Monte Rosa Therapeutics
Monte Rosa Therapeutics is focused on advancing molecular glue degrader (MGD) technology to treat diseases that are currently difficult to target. With a team driven by innovation and passion for medicine, they are shaping the future of medicine through their proprietary platform, QuEEN™, and strategic collaborations. Their mission is to develop transformative therapies for autoimmune, inflammatory, and oncological diseases, leveraging AI and structural biology to expand the druggable target space.
Industries
Nr. of Employees
medium (51-250)
Monte Rosa Therapeutics
Products
VAV1-directed molecular glue degrader (clinical candidate)
An orally bioavailable investigational MGD that selectively degrades VAV1 to modulate T- and B-cell receptor-mediated signaling for immune-mediated diseases; advanced into clinical studies with a global development and commercialization license to an external partner.
NEK7-directed molecular glue degrader (clinical candidate)
An orally bioavailable investigational MGD targeting NEK7 to inhibit NLRP3 inflammasome activation and reduce IL-1β/IL-18 release for inflammatory indications; shown to produce durable target degradation and IL-1β reduction in non-human primate studies and to have favorable GLP toxicology findings.
GSPT1-directed molecular glue degrader (clinical candidate)
An orally bioavailable MGD that recruits an E3 ligase to degrade the translation termination factor GSPT1, exploiting a dependency in MYC-driven cancers to preferentially disrupt protein synthesis and produce anti-tumor activity; advanced into Phase 1/2 clinical evaluation.
Cyclin E1 / CDK2-directed degrader programs (discovery)
Discovery-stage MGDs that selectively degrade Cyclin E1 (CCNE1) and CDK2 to target CCNE1-amplified tumors and certain breast cancers; programs are in lead optimization and chemical development.
Discovery-stage MGD programs across multiple targets
Multiple discovery-stage projects aimed at I&I (immunology & inflammation), genetic diseases, oncology, and selected neurological indications using the same targeted protein degradation approach.
VAV1-directed molecular glue degrader (clinical candidate)
An orally bioavailable investigational MGD that selectively degrades VAV1 to modulate T- and B-cell receptor-mediated signaling for immune-mediated diseases; advanced into clinical studies with a global development and commercialization license to an external partner.
NEK7-directed molecular glue degrader (clinical candidate)
An orally bioavailable investigational MGD targeting NEK7 to inhibit NLRP3 inflammasome activation and reduce IL-1β/IL-18 release for inflammatory indications; shown to produce durable target degradation and IL-1β reduction in non-human primate studies and to have favorable GLP toxicology findings.
GSPT1-directed molecular glue degrader (clinical candidate)
An orally bioavailable MGD that recruits an E3 ligase to degrade the translation termination factor GSPT1, exploiting a dependency in MYC-driven cancers to preferentially disrupt protein synthesis and produce anti-tumor activity; advanced into Phase 1/2 clinical evaluation.
Cyclin E1 / CDK2-directed degrader programs (discovery)
Discovery-stage MGDs that selectively degrade Cyclin E1 (CCNE1) and CDK2 to target CCNE1-amplified tumors and certain breast cancers; programs are in lead optimization and chemical development.
Discovery-stage MGD programs across multiple targets
Multiple discovery-stage projects aimed at I&I (immunology & inflammation), genetic diseases, oncology, and selected neurological indications using the same targeted protein degradation approach.
Services
Discovery collaborations and licensing
Collaborative discovery and licensing agreements to co-develop targeted protein degraders with external partners, including shared development and commercialization arrangements.
Preclinical evaluation and IND-enabling programs
Nonclinical development services including in vivo efficacy studies, GLP toxicology, PK/PD assessments, and preparation of IND-enabling datasets.
Early-phase clinical development
Design and conduct of first-in-human and Phase 1/2 clinical trials to assess safety, tolerability, and preliminary efficacy of investigational degrader candidates.
Discovery collaborations and licensing
Collaborative discovery and licensing agreements to co-develop targeted protein degraders with external partners, including shared development and commercialization arrangements.
Preclinical evaluation and IND-enabling programs
Nonclinical development services including in vivo efficacy studies, GLP toxicology, PK/PD assessments, and preparation of IND-enabling datasets.
Early-phase clinical development
Design and conduct of first-in-human and Phase 1/2 clinical trials to assess safety, tolerability, and preliminary efficacy of investigational degrader candidates.
Expertise Areas
- Targeted protein degradation
- Molecular glue degrader discovery
- Structure-based drug design
- AI/ML-driven drug discovery
Key Technologies
- Molecular glue degrader chemistry
- Geometric deep learning
- AI/ML virtual screening
- Cryo-electron microscopy